PAH stops at nothing.

Show it you won’t either.

Watch the Video
PAH can progress silently
Don’t wait to ask for information.
Learn More
Even on a good day, your PAH may be progressing1
Your PAH may be progressing silently, even when your symptoms seem stable.1
PAH can involve changes in the levels of three substances that occur naturally in your body. Over time, these changes can cause the arteries in your lungs to become thick and stiff. As this happens, the arteries of your lungs may tighten or narrow and scar, making it more difficult for blood to flow. When blood flow is restricted, your heart must work harder to pump blood through the arteries of your lungs. This can cause the muscles in your heart to thicken, which can make it more difficult for your heart to pump blood. As time goes on, the strain on your heart can progressively worsen.2,3
Learn more
Considering every pathway is key
Arteries in the lungs may be affected when there is either too much or too little of three naturally occurring substances in your body, but there are medications available that can target each of these three key pathways.2
Nitric Oxide Pathway
Phosphodiesterase type-5 inhibitors (PDE-5 inhibitors) work here.2
Endothelin Pathway
Endothelin receptor antagonists (ERAs) work here.2
Prostacyclin Pathway
Prostacyclin, prostacyclin analogs, and prostacyclin receptor agonists work here.2
When you have PAH, your body may produce too little of a substance called prostacyclin. Prostacyclin activates a process that helps open arteries.2,3 UPTRAVI® (selexipag) works in a similar way to help open the arteries.4
Take the quiz to test your knowledge of PAH
Take the quiz to test your knowledge of PAH
Take the Quiz
There are steps you can take that may delay PAH progression and it starts with talking to your doctor.
In a clinical trial
UPTRAVI® reduced the risk of PAH disease progression* by 40%.4
27% of patients treated with UPTRAVI® experienced a PAH disease progression event vs 41.6% of patients not taking UPTRAVI®.4
UPTRAVI® reduced the risk of PAH-related hospitalizations. This benefit was demonstrated in a clinical trial comparing patients taking UPTRAVI® to those not taking UPTRAVI®. Patients took UPTRAVI® for an average of 1.4 years.4
In this same clinical trial, patients taking UPTRAVI® walked an average of 12 meters (about 39 feet) farther than patients not taking UPTRAVI®, as measured by the 6-minute walk distance (6MWD).4
*In a clinical trial of UPTRAVI®, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.
How the study was conducted:
UPTRAVI® was studied in the largest trial of any FDA-approved PAH treatment4
  • The trial included 1156 total PAH patients.
    • Compared 574 patients taking UPTRAVI® with 582 patients taking placebo (a sugar pill)
  • 80% of enrolled patients were treated with an endothelin receptor antagonist (ERA), phosphodiesterase type-5 inhibitor (PDE-5 inhibitor), or both for PAH
  • 20% of enrolled patients were not on any PAH treatment
  • Nearly all patients were FC II or FC III (PAH patients range from FC I to FC IV)
  • Patients taking UPTRAVI® were treated for an average of 1.4 years during this study
  • The trial included the most scleroderma-related PAH patients of any PAH trial (170 out of 1156)5,6
You may be able to delay PAH progression. Don't delay in asking your doctor how.
An aggressive disease like PAH may call for an aggressive treatment approach. Learn how to discuss UPTRAVI® with your doctor and start exploring an additional angle to help delay PAH disease progression by downloading this doctor discussion guide.
DOWNLOAD DOCTOR DISCUSSION GUIDE
Facing PAH isn’t easy, but you don’t have to do it alone.
Caregivers can play an essential role in helping you face PAH in the following ways:
  • Helping you learn more about PAH
  • Supporting you at doctor’s appointments
  • Keeping an eye on your good and not-so-good days
  • Advocating on your behalf with your healthcare team
Even on a good day, your PAH
could be progressing1
PAH Progression Definition
In a clinical study of UPTRAVI®, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.
IMPORTANT SAFETY INFORMATION
EXPAND +
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
  • Do not take UPTRAVI® if you are allergic to selexipag or any of the ingredients in UPTRAVI®
  • Before you take UPTRAVI®, tell your healthcare provider about all your medical conditions, including if you:
    • Have liver problems
    • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
    • Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby
    • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
    • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

What are the possible side effects of UPTRAVI®?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain, redness or swelling at the injection site with UPTRAVI® for injection
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI® and all other medicines away from children.

What other medicines might interact with UPTRAVI®?

UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI®?
UPTRAVI® Tablets
  • Take UPTRAVI® exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI® twice a day. Taking UPTRAVI® with food may help you tolerate UPTRAVI® better
  • Swallow UPTRAVI® tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI®
  • UPTRAVI® is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
UPTRAVI® given by intravenous (IV) injection
  • Your healthcare provider will give you UPTRAVI® into your vein through an intravenous (IV) line
  • Your healthcare provider will decide how much UPTRAVI® for injection you will receive each day based on your current dose of UPTRAVI® tablets
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

cp-113991v5

+
IMPORTANT SAFETY INFORMATION
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
+
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension

IMPORTANT SAFETY INFORMATION
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
  • Do not take UPTRAVI® if you are allergic to selexipag or any of the ingredients in UPTRAVI®
  • Before you take UPTRAVI®, tell your healthcare provider about all your medical conditions, including if you:
    • Have liver problems
    • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
    • Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby
    • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
    • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

What are the possible side effects of UPTRAVI®?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain, redness or swelling at the injection site with UPTRAVI® for injection
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI® and all other medicines away from children.

What other medicines might interact with UPTRAVI®?

UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI®?
UPTRAVI® Tablets
  • Take UPTRAVI® exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI® twice a day. Taking UPTRAVI® with food may help you tolerate UPTRAVI® better
  • Swallow UPTRAVI® tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI®
  • UPTRAVI® is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
UPTRAVI® given by intravenous (IV) injection
  • Your healthcare provider will give you UPTRAVI® into your vein through an intravenous (IV) line
  • Your healthcare provider will decide how much UPTRAVI® for injection you will receive each day based on your current dose of UPTRAVI® tablets
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

cp-113991v5

References: 1. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143-155. 2. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189-2208. 3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294. 4. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 5. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50(2). 6. Aithala R, Alex A, Debashish D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis. 2017;20:5-24.